All News

A session at the Association of Community Cancer Centers (ACCC) 2023 Annual Meeting and Cancer Center Business Summit highlighted ongoing issues in oncology policy and payment, from the Cures 2.0 Act to 340B drug reimbursement.

Body mass index and nadir CD4 count were major factors in SARS-CoV-2 humoral immune repertoire among people with HIV.

In a recent webinar, health care experts discussed how addressing social determinants of health by investing in various areas can benefit patients and payers.

When a series of winter storms in Austin, Texas, in February 2021, 62% of children with epilepsy were negatively affected, according to a new study.

Jeff Hunnicutt, CEO of Highlands Oncology Group, explains the 2 risk options provided under the Enhancing Oncology Model (EOM) and why the mandatory downside risk might give pause to practices that saw some success in the Oncology Care Model.

A meta-analysis and review of 9 randomized trials found high-quality evidence demonstrating the benefits of dupilumab in patients with severe atopic dermatitis.

These new findings suggest that variability in factor VIII (FVIII) half-life in patients, though impacted by all 3 factors, is largely attributed to variability in the clearance of endogenous von Willebrand factor (VWF).

Coverage of our peer-reviewed research and news reporting in the health care and mainstream press.

A study of Navy sailors and Marines from the United States found that only 7.7% of participants had neutralizing antibodies for the Omicron variant 8 months after vaccination.

Myasthenia gravis affects about 60,000 individuals in the United States.

As scientists are identifying molecular alterations in patients with later-stage cancers that may be targets in earlier-stage disease, next-generation sequencing is being utilized more in the first-line setting, noted Sigrun Hallmeyer, MD, medical oncologist with Advocate Health.

A new study examining sleep irregularity and sleep duration found that sleep irregularity was associated with several indictors of heart disease.

The prevalence of comorbidities in patients with severe chronic obstructive pulmonary disease (COPD), including impaired kidney function, are predictors of long-term mortality, study finds.

Kevin Davies, PhD, executive editor, The CRISPR Journal and GEN Biotechnology, discusses how CRISPR has evolved from the initial discovery of the double helix to now, with the technology holding great promise for both genetic diseases and cancers.

Researchers found that only 8 of 18 HIV risk assessment models have been externally validated and show moderate-to-good discrimination ability for HIV infection prediction.

A session at the ACCC 2023 Annual Meeting and Cancer Center Business Summit addressed the promise and potential drawbacks of multicancer early detection (MCED) testing for patients in the primary care setting.

In the first keynote session at the ACCC 2023 Annual Meeting and Cancer Center Business Summit, the history of CRISPR genome editing and its potential in cancer and other settings took center stage.

Ganglion cell/inner plexiform layer (GCIPL) and circumpapillary retinal nerve fiber layer (cpRNFL) thinning were both associated with a higher risk of developing perimetric glaucoma.

Andre Harvin, PharmD, MS, MBA, Cone Health Cancer Center, discusses the vital role of pharmacists in oncology: how they use data to streamline patient visits, work to facilitate patient access to biosimilars, and advocate for their patients.

There is clearly an important role for teplizumab to treat type 1 diabetes (T1D) right now, said Kevan Herold, MD, professor of immunobiology and medicine at Yale School of Medicine.

A combination of evidence-based interventions and team-based approaches shows efficacy in helping physicians care for patients with chronic obstructive pulmonary disease (COPD), according to one study.

Panelists at the keynote session of the Value-Based Insurance Design Summit highlighted what their organizations are doing in health equity.

Medicaid plans begin planning for the upcoming lapse in continuous coverage starting April 1, 2023; Bayer plans to spend $1 billion on US pharmaceutical research and development in 2023; opioids were the most common cause of death by poisoning in young children.

Given the cost and impact of chronic diseases on the US health care system, health technology like digital coaching for chronic diseases is increasingly being looked at as a way to offer personalized therapies on a wide scale.

Researchers from Brigham and Women’s Hospital and Massachusetts General Hospital identified new targets for small molecule drugs to counter Clostridioides difficile colonization and infection (CDI) in the gut and provide a new approach to rapidly define microbial metabolism for other applications.

A new resource from the National Alliance of Healthcare Purchaser Coalitions aims to help plan sponsors adopt biosimilars into their pharmacy benefit plans.

The FDA approved the VENTANA PD-L1 assay for expanded use in patients with advanced non–small-cell lung cancer to help identify patients who may be candidates for treatment with cemiplimab.

The extended follow-up results are consistent with the primary analysis of the CLEAR trial, supporting the increased efficacy of first-line lenvatinib plus pembrolizumab compared with sunitinib in patients with advanced renal cell carcinoma.